By: Dr. Uwe Hanenberg, Head of Product Development, Oral Solid Dose, Recipharm
A new generation of complex therapeutics could advance the treatment options for patients with chronic conditions, from rare genetic disorders to autoimmune diseases.
But this great potential comes with challenges. These new modalities, including messenger RNA (mRNA) and the advanced formulation vehicles used to deliver them, such as lipid nanoparticles (LNPs), are inherently fragile.
To stabilize these forms, many drug developers employ lyophilization. Also known as freeze-drying, this process meticulously removes water from a frozen solution under vacuum conditions, leaving behind dry, solid matter with a much longer shelf life.
This article details the lyophilization process for next-generation therapeutics, covers key considerations for optimization and explores the complexities of scaling up for commercial production.
How Lyophilization Enhances Shelf Life
Lyophilization involves three distinct processes:
- Freezing: The therapeutic is cooled to a temperature below its freezing point, solidifying the water content. This step determines the product’s ice crystal structure, which affects its drying stages.
- Primary drying (sublimation): The frozen product is placed inside a vacuum and heated. This causes the ice to sublimate and transition from a solid to a gaseous state, thereby shedding the bulk of thewater.
- Secondary drying (desorption): In this final stage, the residual unfrozen water molecules bound to the solid material are removed by raising the temperature.
By removing a product’s water content, these processes significantly inhibit any microbial growth and enzymatic activity, enhancing the product’s shelf life at temperatures beyond ambient conditions. Because of these qualities, lyophilized products can be stored and moved outside of ultra-cold storage, a handling benefit that can cut a drug developer’s transportation costs significantly.
Lyophilization Challenges Under the Spotlight
Although lyophilization offers clear benefits for fragile therapeutics, it also presents several challenges, as seen in the production of mRNA-based drugs. These molecules are intrinsically delicate and prone to degradation under the stresses of freezing and drying. The LNPs commonly used for mRNA delivery may also experience structural alterations or aggregation during the freezing and drying stages, which can compromise their ability to encapsulate and transport the therapeutic payload effectively.
As a result, optimizing cryoprotectant formulations and tightly controlling freezing and drying parameters are essential to preserving both mRNA integrity and LNP functionality after reconstitution.
As more next-generation therapeutics progress through development pipelines, contract development and manufacturing organisations (CDMOs) must possess the expertise and capabilities required to address the challenges of lyophilising these advanced products, ensuring they can successfully reach the market and, ultimately, patients.
Preparing for Lyophilization Hurdles
Successfully navigating these challenges calls for a careful and well-informed approach to formulation and process development. For CDMOs working with advanced therapeutics, success in lyophilization depends on getting several interdependent factors right, from excipient selection to cycle design and final product assessment. With that in mind, there are three core considerations that any partner managing the lyophilization stage should understand:
1. Choosing an excipient
Excipient choice plays a central role in the formulation of lyophilized drug products. Commonly used excipients include sugars such as sucrose and trehalose, as well as polyols like mannitol and sorbitol. Cryoprotectants are typically included to safeguard biomolecules during the freezing stage, while lyoprotectants help preserve active ingredients throughout drying. Both function by substituting for water molecules, thereby reducing the risk of denaturation.
It is important that excipients are compatible with the active pharmaceutical ingredients (APIs) and other formulation components and that their concentrations and ratios are carefully balanced to ensure effective protection without compromising product quality.
Analytical tools like differential scanning calorimetry (DSC) can help assess an excipient’s thermal properties, guiding cryoprotectant selection, while molecular interaction can be studied using Fourier-transform infrared (FTIR) or Raman spectroscopy.
Beyond these protective agents, buffer systems are also essential, as they help maintain stable pH levels during freezing, preventing fluctuations that could otherwise damage the formulation.
2. Optimizing the lyophilization cycle
The lyophilzation cycle is dependent on reliable freezing protocols. These practices, which are essential for efficient primary drying, may center on techniques such as controlled nucleation to achieve consistent ice crystal formation or annealing steps to encourage the growth of larger, more stable crystals.
During primary drying, temperature ramping and pressure must be carefully managed to support effective ice sublimation while avoiding potential complications. Secondary drying must also be precisely controlled to remove residual, tightly bound water and reach the desired moisture level. Achieving this requires careful adjustment of temperature and drying duration to ensure sufficient dryness without compromising product stability through degradation.
3. Characterizing the finished product
Thorough characterisation of the finished product is essential for ensuring quality and evaluating stability, especially in particulate-based delivery systems. Techniques such as dynamic light scattering (DLS) and microscopy are commonly used to assess particle size and distribution. In addition, the structural integrity of the therapeutic molecule is analyzed using methods like high-performance liquid chromatography (HPLC) and electrophoresis.
To support long-term stability, residual moisture levels are measured using approaches such as Karl Fischer titration and thermogravimetric analysis (TGA). Stability studies conducted under a range of storage conditions, combined with predictive modelling of degradation behavior, generate key data for defining shelf life and establishing appropriate storage requirements.
The Complexities of Scaling Up for Commercialization
The list of considerations a CDMO must keep in mind when managing lyophilization only grows when a drug is produced at a commercial level, especially if the drug has a complex formulation.
Ensuring quality and uniformity
Maintaining consistent quality and uniformity becomes more challenging as batch sizes increase. In large-scale lyophilization systems, complex chamber geometries can lead to uneven heat and mass transfer. Resistance to water vapor flow will also be higher, which can affect drying rates depending on the position of vials within the chamber. Additionally, heat transfer is not uniform, meaning vials at the edges of the chamber tend to receive more radiant heat than those located centrally. As a result, variations in drying behavior and residual moisture content can occur across the batch.
To promote uniform sublimation, several control approaches can be applied. During primary drying, dual vacuum probes may be used to monitor water vapor flow at different concentrations within the chamber. In scale-up scenarios, temperature sensors such as Tempris probes can be placed in representative vials to track ice temperature in real time, supporting optimization of drying conditions.
A pressure rise test can be employed at the end of primary drying to assess whether ice for continuing sublimation; any rise in chamber pressure after isolation would indicate that residual ice is still present. Performing this test, however, can sometimes cause product collapse.
To avoid this risk, another indicator of desorption progress, product temperature, can be monitored during secondary drying. This phase of drying usually raises chamber temperatures further, by 20-40°C. To ensure the desorbing of residual water molecules, operators should continue to monitor the data from the Tempris probes, correlating any temperature changes with pressure data.
If sublimation and desorption are not properly controlled, issues such as uneven residual moisture, partial melting or microcollapse may arise in certain vials. These inconsistencies can lead to undesired outcomes that undermine the very stability intended by the lyophilization process, including extended reconstitution times, reduced stability and product degradation. Applying advanced monitoring and control strategies helps ensure consistent processing across large batches, supporting product uniformity, stability and reliable quality.
Optimizing cycle times and equipment selection
In commercial manufacturing, achieving efficient cycle times is essential to meet demand and manage costs. However, accelerating the process too aggressively can compromise product quality, making it necessary to strike a balance between speed and integrity. Careful selection of lyophilization equipment is therefore critical. Different systems, such as tray and manifold lyophilizers, are suited to varying production scales, while ongoing innovations, including process analytical technology (PAT) for real-time monitoring and automated loading and unloading systems, are enhancing both efficiency and process control in large-scale operations.
Other technical additions to this stage include the use of tuneable diode laser absorption spectroscopy (TDLAS) to measure water vapor concentration and the use of near-infrared spectroscopy (NIR) to monitor moisture and temperature within vials.
Navigating compliance
Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose stringent requirements on lyophilized products. These include the need for extensive stability studies to confirm long-term performance under a range of conditions, as well as strict compliance with good manufacturing practice (GMP) across all stages of production. Failure to meet these standards can result in delays and high additional costs, underscoring the need for a CDMO to incorporate regulatory considerations early in its scale-up process.
The Future of Lyophilization: Expanding Access to Next-Generation Therapies
Ultimately, any CDMO managing lyophilisation at a commercial scale should have a holistic approach that takes into account all aforementioned considerations, from excipient choice to regulatory compliance.
As freeze-drying continues to evolve, this strategy also needs to stay flexible and adapt to any new priorities that emerge. For example, researchers are currently exploring microfluidic approaches to lyophilization, which could offer more precise control over LNP particle size and uniformity.
Drug developers looking to bolster their LNP and mRNA vaccine offerings would therefore be wise to partner with a CDMO with significant lyophilization capabilities and experience, one that can provide critical support throughout a drug’s journey from initial manufacturing to scaling. These are the kinds of partners that can help bring new, transformative treatments to patients efficiently, safely and reliably.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!